GlassScriptPhysician profile
Edward D Himot
NPI 1639173248
$5,474.75
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,407 · 2020: $85.01 · 2021: $200 · 2022: $215 · 2023: $329 · 2024: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519 · Education: $49.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.69 |
| Education | $49.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rockwell Medical, INC. | $3,383.43 | 2019 | |
| Fresenius USA Marketing, INC. | $292.01 | 2019-2024 | |
| Vifor Pharma, INC. | $270.21 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $253.31 | 2019-2023 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $248.71 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $192.50 | 2019-2024 | Tavneos |
| Travere Therapeutics, INC. | $134.87 | 2022-2024 | |
| Horizon Therapeutics Plc | $114.20 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $104.72 | 2019-2024 | Vafseo |
| Alexion Pharmaceuticals, INC. | $82.97 | 2019-2023 | Ultomiris |
| Daiichi Sankyo INC. | $72.56 | 2019-2023 | Injectafer |
| Shire North American Group INC | $54.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.48 | 2023 | |
| Janssen Pharmaceuticals, INC | $43.62 | 2019-2024 | Xarelto |
| Mallinckrodt Enterprises LLC | $29.19 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.28 | 2020 | |
| Lundbeck LLC | $22.45 | 2019 | |
| Calliditas Therapeutics US INC. | $21.74 | 2023 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $19.84 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.72 | 2019 | |
| Glaxosmithkline, LLC. | $17.73 | 2023 | Benlysta |
| Takeda Pharmaceuticals U.S.A., INC. | $16.32 | 2020 | |
| La Jolla Pharmaceutical Company | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Himot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.